Terms: = Prostate cancer AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Prognosis
1652 results:
1. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
2. [Bioinformatics-based analysis of the effect of general Transcription Factor IIH on prognosis of prostate cancer].
Li JC; Zhu XJ; Ye JH; Tan ZH; Cai SH; Deng YL; Chen J; Tian WC; Luo DH; Zhong WD
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1410-1417. PubMed ID: 38644292
[No Abstract] [Full Text] [Related]
3. Prognostic significance of tumor suppressor protein p53 in prostate cancer.
Ben Rejeb S; Kouki N; Elfekih S; Cherif I; Khouni H
Tunis Med; 2024 Feb; 102(2):111-115. PubMed ID: 38567478
[TBL] [Abstract] [Full Text] [Related]
4. Primary mucinous adenocarcinoma of the urethra: A contemporary clinicopathologic analysis of 17 patients.
Alrohaibani A; Osunkoya AO
Pathol Res Pract; 2024 Apr; 256():155273. PubMed ID: 38565023
[TBL] [Abstract] [Full Text] [Related]
5. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
[TBL] [Abstract] [Full Text] [Related]
6. Midterm outcomes of transcatheter aortic valve replacement in patients with active cancer.
Noguchi M; Tabata M; Ito J; Kato N; Obunai K; Watanabe H; Yashima F; Watanabe Y; Naganuma T; Yamawaki M; Yamanaka F; Shirai S; Ueno H; Tada N; Yamamoto M; Hayashida K;
Open Heart; 2024 Feb; 11(1):. PubMed ID: 38417913
[TBL] [Abstract] [Full Text] [Related]
7. A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial.
Smith TAD; West CML; Joseph N; Lane B; Irlam-Jones J; More E; Mistry H; Reeves KJ; Song YP; Reardon M; Hoskin PJ; Hussain SA; Denley H; Hall E; Porta N; Huddart RA; James ND; Choudhury A
EBioMedicine; 2024 Mar; 101():105032. PubMed ID: 38387404
[TBL] [Abstract] [Full Text] [Related]
8. Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer.
Sun J; Tian T; Wang N; Jing X; Qiu L; Cui H; Liu Z; Liu J; Yan L; Li D
Front Endocrinol (Lausanne); 2024; 15():1338420. PubMed ID: 38384968
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic Value of the Modeled prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant prostate cancer Treated With Taxanes in FIRSTANA.
Carrot A; Oudard S; Colomban O; Fizazi K; Maillet D; Sartor O; Freyer G; You B
JCO Clin Cancer Inform; 2024 Feb; 8():e2300208. PubMed ID: 38364191
[TBL] [Abstract] [Full Text] [Related]
10. Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant prostate cancer.
Saylor PJ; Otani K; Balza R; Ukleja J; Pleskow H; Fisher R; Kusaka E; Otani YS; Badusi PO; Smith MR; Meneely E; Olivier K; Lowe AC; Toner M; Maheswaran S; Haber DA; Yeap BY; Lee RJ; Miyamoto DT
JCO Precis Oncol; 2024 Feb; 8():e2300230. PubMed ID: 38354328
[TBL] [Abstract] [Full Text] [Related]
11. Copy Number Gain in Androgen Receptors Predicts the Poor prognosis in Japanese Castration-resistant prostate cancer.
Sakamoto S; Ando K; Pae S; Zhao X; Sakai K; Sato K; Saito S; Yamada Y; Rii J; Goto Y; Sazuka T; Imamura Y; Anzai N; Akakura K; Nishio K; Ichikawa T
Anticancer Res; 2024 Feb; 44(2):639-647. PubMed ID: 38307556
[TBL] [Abstract] [Full Text] [Related]
12. prostate cancer Risk Stratification by Simple Scoring of the Current pT3 Lesions: A Proposal for a New Pathologic T-Staging System.
Miyamoto H; Teramoto Y; Numbere N; Wang Y; Joseph JV
Mod Pathol; 2024 Mar; 37(3):100429. PubMed ID: 38266919
[TBL] [Abstract] [Full Text] [Related]
13. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
14. Dosiomics for intensity-modulated radiotherapy in patients with prostate cancer: survival analysis stratified by baseline prostate-specific antigen and Gleason grade group in a 2-institutional retrospective study.
Murakami Y; Kawahara D; Soyano T; Kozuka T; Takahashi Y; Miyake K; Kashihara K; Kashihara T; Kamima T; Oguchi M; Murakami Y; Yoshioka Y; Nagata Y
Br J Radiol; 2024 Jan; 97(1153):142-149. PubMed ID: 38263831
[TBL] [Abstract] [Full Text] [Related]
15. Functional Outcomes After Localized prostate cancer Treatment.
Al Hussein Al Awamlh B; Wallis CJD; Penson DF; Huang LC; Zhao Z; Conwill R; Talwar R; Morgans AK; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; O'Neil BB; Koyama T; Hoffman KE; Barocas DA
JAMA; 2024 Jan; 331(4):302-317. PubMed ID: 38261043
[TBL] [Abstract] [Full Text] [Related]
16. Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy.
Yoshida T; Kawai T; Hagiwara K; Yanagida K; Noda M; Tokura Y; Yoshimura I; Kaneko T; Nakagawa T
Jpn J Clin Oncol; 2024 Apr; 54(4):498-503. PubMed ID: 38251778
[TBL] [Abstract] [Full Text] [Related]
17. Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients.
Falkenbach F; Kachanov M; Leyh-Bannurah SR; Maurer T; Knipper S; Köhler D; Graefen M; Sauter G; Budäus L
World J Urol; 2024 Jan; 42(1):38. PubMed ID: 38244095
[TBL] [Abstract] [Full Text] [Related]
18. High-resolution MRI synthesis using a data-driven framework with denoising diffusion probabilistic modeling.
Chang CW; Peng J; Safari M; Salari E; Pan S; Roper J; Qiu RLJ; Gao Y; Shu HK; Mao H; Yang X
Phys Med Biol; 2024 Feb; 69(4):. PubMed ID: 38241726
[No Abstract] [Full Text] [Related]
19. Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift.
Tantawy MN; McIntyre JO; Yull F; Calcutt MW; Koktysh DS; Wilson AJ; Zu Z; Nyman J; Rhoades J; Peterson TE; Colvin D; McCawley LJ; Rook JM; Fingleton B; Crispens MA; Alvarez RD; Gore JC
Cancer Med; 2024 Feb; 13(3):e6812. PubMed ID: 38239047
[TBL] [Abstract] [Full Text] [Related]
20. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
[TBL] [Abstract] [Full Text] [Related]
[Next]
